Facebook
Twitter
LinkedIn
Forward
State of the Art Imaging in the Diagnosis and Management of Prostate Cancer
This is a Hybrid Course
Staying abreast of the rapidly advancing field of prostate imaging is paramount to the successful staging and treatment of patients with prostate cancer. This one-day CME course, State of the Art Imaging in the Diagnosis and Management of Prostate Cancer, will discuss current and new developments in multiparametric MRI (mpMRI), MRI-ultrasound fusion biopsy, including transperineal biopsy, PSMA PET imaging, focal therapy treatment options, and other recent advances in imaging technology and diagnostics/therapeutics for prostate cancer. The course is designed to provide a focused, yet comprehensive advanced clinical review for practicing urologists, radiologists, medical oncologists, and radiation oncologists, as well as advanced practice providers. Participant learning and interaction will be encouraged through case reviews, question-and-answer sessions, and interaction with the course faculty.
| Registration Type | Tuition Fee |
|---|---|
| In-Person | $250.00 |
| Virtual | $200.00 |
Target Audience
This activity is intended for physicians, nurses, physician assistants, and other members of the healthcare team.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Define the most up-to-date imaging evaluation of patients with localized and advanced prostate cancer.
- Assess upcoming novel imaging techniques for the evaluation of prostate cancer.
- Describe imaging-based diagnostic and therapeutic procedural modalities including fusion biopsy and focal therapy.
- Apply the most current state-of-the-art mpMRI imaging in the care of prostate cancer patients or those with a suspicion of prostate cancer.
- Develop strategies for the healthcare team to incorporate MRI-ultrasound fusion prostate biopsy in clinical practice.
- Integrate the most current pathophysiological and pathological concepts into the interpretation of mpMRI.
FOR EXHIBIT SPACE, PLEASE CONTACT EBROOKS3@MGB.ORG
Additional Information
Massachusetts General Hospital Cancer Center & Mass General Brigham
| 7:00am | Registration and Breakfast |
| 7:40 | Introduction and Welcome | Adam S. Feldman, MD, MPH & Mukesh Harisinghani, MD |
Session 1: Imaging of the Prostate for Diagnosis | |
| 7:45 | Multiparametric MRI – Current State of the Art and Future Directions | Mukesh Harisinghani, MD |
| 8:15 | MRI in the Patient with an Elevated PSA – Standard of Care | Speaker TBD |
| 8:45 | Utilization of Other Diagnostics/Biomarkers | Keyan Salari, MD, PhD |
| 9:15 | What to do After Negative Prostate MRI | Adam Feldman, MD, MPH |
| 9:35 | Break |
Session 2: Imaging of the Prostate for Treatment | |
| 10:00 | Imaging for Staging and Treatment Planning — Surgery | Adam Kibel, MD |
| 10:30 | Imaging for Staging and Treatment Planning — Radiation | Jason Efstathiou, MD, DPhil |
| 11:00 | PSMA and Molecular Imaging of Prostate Cancer | Baris Turkbey, MD |
| 11:30 | Imaging of Advanced Disease | Philip Saylor, MD |
| 12:00pm | Lunch |
Session 3: MRI-Guided Diagnostics and Treatment | |
| 12:45 | Transperineal Prostate Biopsy | Douglas Dahl, MD |
| 1:10 | Utilization of MRI and Fusion Biopsy in the Active Surveillance Patient | TBD |
| 1:35 | Utilization of Focal Therapy: When Is It Appropriate? | Alexander Cole, MD |
| 2:00 | Break |
Session 4: Case-Based Panel Discussions | |
| 2:15 | Diagnostic Dilemmas | Rory Cochran, MD, PhD; Brent Hollenbeck, MD, MS |
| 2:45 | The Active Surveillance Patient | Baris Turkbey, MD; Matthew Wszolek, MD; Anthony Zietman, MD |
| 3:15 | Locally Advanced Disease | Douglas Dahl, MD; Mukesh Harisinghani, MD; Sophia Kamran, MD |
| 3:45 | Metastatic Prostate Cancer | Rory Cochran, MD, PhD; Jason Efstathiou, MD, DPhil; Richard J. Lee, MD |
| 4:15pm | Thank you and Adjourn |
Course Director
Adam S. Feldman, MD, MPH
Massachusetts General Hospital Cancer Center
Faculty
Rory Cochran, MD, PhD
Massachusetts General Hospital
Alexander Cole, MD
Brigham and Women’s Hospital
Douglas Dahl, MD
Massachusetts General Hospital
Jason Efstathiou, MD, DPhil
Massachusetts General Hospital
Mukesh Harisinghani, MD
Massachusetts General Hospital
Brent Hollenbeck, MD, MS
Massachusetts General Hospital
Sophia Kamran, MD
Massachusetts General Hospital
Adam Kibel, MD
Brigham and Women’s Hospital
Richard J. Lee, MD
Massachusetts General Hospital Cancer Center
Keyan Salari, MD, PhD
Massachusetts General Hospital
Philip Saylor, MD
Massachusetts General Hospital Cancer Center
Baris Turkbey, MD
National Institute of Health
Matthew Wszolek, MD
Massachusetts General Hospital
Anthony Zietman, MD
Massachusetts General Hospital
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AMA PRA Category 1 CreditsTM
Mass General Brigham designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
Mass General Brigham designates this activity for 7.25 ANCC contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.
Available Credit
- 7.25 AMA PRA Category 1 Credit™
- 7.25 Nursing Contact Hours
- 7.25 Participation
Price
| Registration Type | Tuition Fee |
|---|---|
| In-Person | $250.00 |
| Virtual | $200.00 |
Cancellation Policy:
Registrations cancelled on or before October 18, 2024 will be refunded, less a $35 administrative fee. Registrations cancelled after October 18, 2024 will not be refunded.
Contact partnerscpd@partners.org if you require assistance in cancelling your online registration.